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Abstract
OBJECTIVE—Prevention of influenza among infants and young children is a public health 
priority because of their high risk for influenza-related complications. Depending on a child’s age 
and previous influenza vaccination history, they are recommended to receive either 1 dose or 2 
doses of influenza vaccine to be considered fully vaccinated against influenza for the season. We 
compared estimates of full (complete) influenza vaccination coverage of children 6 to 23 months 
across 10 consecutive influenza seasons (2002–2012), by race/ethnicity, age group, and by number 
of doses required to be fully vaccinated given child’s vaccination history.
METHODS—National Immunization Survey data were used to estimate full influenza 
vaccination status among children 6 to 23 months on the basis of provider report. Estimates were 
computed by using Kaplan-Meier survival analysis methods.
RESULTS—Full influenza vaccination coverage among children 6 to 23 months increased from 
4.8% in the 2002–2003 influenza season to 44.7% in the 2011–2012 season. In all 10 influenza 
seasons studied, non-Hispanic black children and Hispanic children had lower full influenza 
vaccination coverage than non-Hispanic white children. For all 10 influenza seasons, full influenza 
vaccination coverage was higher among children requiring only 1 dose compared with those 
requiring 2 doses.
CONCLUSIONS—Less than half of children 6 to 23 months in the United States, and an even a 
smaller percentage of Hispanic and non-Hispanic black children, are fully vaccinated against 
influenza. More implementation of evidence-based strategies that increase the percentage of 
children who are fully vaccinated is needed.
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Prevention of influenza among infants and young children is a public health priority because 
of their high risk for influenza-related complications. Before 2002, recommendations for 
influenza vaccination of children in the United States focused on those with health 
conditions that confer increased risk of severe illness from influenza.1 Recommendations for 
the routine annual influenza vaccination of all children were first made in 2002, when the 
Advisory Committee on Immunization Practices (ACIP) voted to encourage providers to 
vaccinate all children aged 6 to 23 months, regardless of medical conditions.2 In 2004, the 
ACIP explicitly recommended vaccination for all children 6 to 23 months.3 Later, in 2006, 
these recommendations were expanded to include all children 6 to 59 months and in 2008 to 
include all children 6 months to 18 years.4,5
Children 6 months through 8 years who are influenza vaccine–naive require 2 doses of 
vaccine for optimal immune response.6,7 The ACIP recommends that children 6 months 
through 8 years receive either 1 dose or two doses spaced at least 4 weeks apart, depending 
on previous influenza vaccination history. The recommendations for determining the needed 
number of doses required to be considered fully vaccinated against influenza have changed 
over time (Table 1). For the 2002–2003 through the 2006–2007 seasons, 2 doses were 
recommended for children who had never received an influenza vaccination previously, 
otherwise 1 dose was recommended. In the 2007–2008 season the recommendation for 2 
doses expanded to include those who should have received 2 doses in the previous season 
but received only 1 dose. The emergence of the pandemic 2009 H1N1 virus (H1N1pdm09) 
ahead of the 2009–2010 influenza season led to the development of the monovalent 
pandemic vaccine, and 2 influenza vaccines were recommended during 2009–2010: the 
trivalent seasonal influenza vaccination and the pandemic influenza A(H1N1)pdm09 
(pH1N1) monovalent vaccine.8 For the 2010–2011 season, given the relative antigenic 
novelty of the p(H1N1) virus, the recommended approach for determining the number of 
doses needed for young children was modified to consider both previous exposure to 
seasonal influenza vaccines and the pH1N1 vaccine.9 During subsequent seasons up through 
the 2014–2015 season, the procedure for determining the number of doses needed continued 
to consider receipt of both seasonal influenza vaccine and the receipt of H1N1pdm09-
containing vaccine (Table 1), with some further variations depending on whether vaccine 
viruses had changed compared with the previous season.10–13
Influenza vaccination coverage with at least 1 dose based solely on parental report (ie, no 
provider verification) has been routinely assessed and reported since 2009, but full 
vaccination coverage has not been assessed since then.19 Obtaining full vaccination coverage 
measures based on parental report is more complicated because it requires the parent to 
remember and report the child’s lifetime history of influenza vaccination. Before the 2009–
2010 season, coverage with at least 1 dose and full coverage based solely on provider-
reported vaccination histories had been assessed among children 6 to 23 months, but these 
reports were discontinued due to lack of timeliness, that is, the estimates for 1 season were 
not available before the start of the next season due to the extended time needed to obtain 
provider-reported vaccination data. Furthermore, nationally representative provider-reported 
data were not available for all of the age groups recommended to receive annual influenza 
vaccination as the recommendations expanded from children 6 to 23 months to all children 6 
months and older.
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This study focuses on children 6 to 23 months because, among children, this age group has 
the highest risk of influenza-related complications, they were the first group of children for 
which a routine influenza recommendation was made, and this is an age group for which 
nationally representative provider-reported influenza vaccination histories are available from 
survey data. The aims of this study were to examine the percentage of children 6 to 23 
months who were fully vaccinated against influenza during each of 10 consecutive influenza 
seasons, by race/ethnicity, age group, and number of doses required to be fully vaccinated 
given the child’s vaccination history. The estimates in this report can serve as a benchmark 
against which full vaccination coverage based on the more timely parental report can be 
compared once these measures are developed for all children 6 months through 8 years.
METHODS
Survey Description
Data from the 2003 through 2012 National Immunization Survey (NIS) were analyzed. The 
NIS is an ongoing, national, list-assisted random-digit-dialed, landline and cellular telephone 
survey of households with children 19 to 35 months.20 Cellular telephones were added to the 
NIS in 2011.21 The household telephone survey is followed by a mailed questionnaire, the 
Immunization History Questionnaire, to all of the immunization providers identified during 
the telephone survey and for which permission to contact them was granted by the parent. 
The influenza vaccination coverage estimates in this report are based only on the provider-
reported vaccinations. Providers reported the entire lifetime history of influenza vaccination 
on the Immunization History Questionnaire for every influenza season for which the child 
had received vaccination. Age was defined based on age on November 1 of the influenza 
season under study, with this study being limited to children who were 6 to 23 months on 
November 1, realizing that some children would age out of this age range during the 
influenza season, but they and all of their vaccinations were included. For each influenza 
season, 2 full calendar years of NIS data files were combined for analysis of the influenza 
season beginning the previous calendar year. For example, to obtain estimates for the 2002–
2003 influenza season, the 2003 and 2004 NIS data files were combined. This was necessary 
to obtain an equal distribution of children throughout the age range of 6 to 23 months. The 
race/ethnicity variable used in this study (Hispanic, non-Hispanic white only, non-Hispanic 
black only, non-Hispanic other or multiple race) is based on parent report of the child’s race 
and ethnicity; children of Hispanic ethnicity may be of any race. The household response 
rates for the NIS data included in this study, as defined by the Council of American Survey 
Research Organizations, ranged from 61.6% to 73.1% for the landline sample (2003–2012) 
and 25.2% to 30.6% for the cellular telephone sample (2011–2012).22 The percentage for 
which adequate provider vaccination records were obtained among children with completed 
household interviews ranged from 63.6% to 72.3%.22 Methodological details of the NIS 
have been previously published.20
Statistical Methods
The Kaplan-Meier survival analysis procedure was used to calculate the percentage of 
children fully vaccinated. The event variable was defined as the provider-reported month of 
the influenza vaccination dose that made the child fully vaccinated against influenza, either 
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the first (or only) dose or the second dose. The number of doses needed was determined on 
the basis of the season-specific recommendations for number of doses required, as 
summarized in Table 1. The Kaplan-Meier method was also used to calculate the percentage 
of children who received at least 1 dose of influenza vaccination (≥1 dose coverage), with 
the event variable defined as the provider-reported month of the child’s first influenza dose 
(regardless of their need for 1 or 2 doses). Influenza vaccinations received during the entire 
influenza season from July through May were included in the coverage estimates. This 
method was used to estimate the percentage of children fully vaccinated against influenza 
overall and by age group, racial/ethnic group, and number of doses required to be fully 
vaccinated, and for the 2011–2012 season only, by state.
Differences between influenza seasons within each group were tested by using t tests. 
Likewise, differences between groups within each influenza season were tested by using 
pairwise comparison t tests. Comparisons reported as being increases or decreases were 
statistically significant, whereas comparisons that were not statistically significant are 
reported as not being different. Reported percentages and corresponding 95% confidence 
intervals were weighted, and reported sample sizes were unweighted. All analyses were 
weighted to population totals, unit nonresponse, and noncoverage of nontelephone 
households and to adjust for households having multiple telephone lines. Tests for linear 
trend were performed using a weighted linear regression on the season-specific estimates 
using season number as the independent variable and weights as the inverse of the estimated 
variance of the estimated vaccination coverage. Pairwise comparisons of estimates were 
conducted by using t tests assuming large degrees of freedom and used the value of 1.96 for 
the critical value. Analyses were conducted by using SAS release 9.3 (SAS Inc, Cary, NC) 
and SUDAAN release 11.0.0 (Research Triangle Institute, Research Triangle Park, NC) 
statistical software to take into account the complex survey design. All statistical tests were 
2-tailed with the significance level set at α < 0.05. Institutional review board approval for 
conducting the NIS was obtained through the National Center for Health Statistics Research 
Ethics Review Board and through the IRB of NORC at the University of Chicago.
RESULTS
Percentage of Children Requiring 2 Doses
Among children 6 to 23 months, the percentage of children requiring 2 doses to be 
considered fully vaccinated varied by influenza season as the dosage recommendations 
changed (Table 1). The percentage of children 6 to 23 months requiring 2 doses to be fully 
vaccinated against influenza ranged from 70.1% for 2011–2012 to 99.2% for the 2002–2003 
season.
Trends in Full Influenza Vaccination Coverage Overall
Full influenza vaccination coverage among children 6 to 23 months overall increased from 
the 2002–2003 influenza season to the 2011–2012 season (trend test P < .001; Table 2; Fig 
1). The average annual increase was 4.2 percentage points based on the slope of the trend 
test. The estimates and annual changes from the previous season are denoted in Table 2. In 
only 2 of the 10 influenza seasons (the 2007–2008 and the 2010–2011 seasons), there was 
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no increase observed in the percentage of children fully vaccinated compared with the 
previous season. Full influenza vaccination coverage by state for the 2011–2012 influenza 
season is presented in Table 3; coverage ranged from 23.6% in Mississippi to 72.2% in 
Massachusetts.
Trends in Full Influenza Vaccination Coverage by Age Group
Within each age group studied, full influenza vaccination coverage increased from the 2002–
2003 influenza season to the 2011–2012 season (trend test P < .001 each; Table 2). In 5 of 
the 10 influenza seasons studied (2003–2004, 2004–2005, 2005–2006, 2006–2007, and 
2011–2012), there were no differences between the age groups in full influenza vaccination 
coverage. In the remaining 5 seasons, children aged 6 to 11 months had higher full influenza 
vaccination coverage than children in the older age groups.
Trends in Full Influenza Vaccination Coverage by Race/Ethnicity
Within all 4 racial/ethnic groups studied, full influenza vaccination coverage increased from 
the 2002–2003 influenza season to the 2011–2012 season (trend test P < .001 each; Table 2). 
The change in vaccination coverage from one season to the next within each group is 
indicated in Table 2 including whether these changes were statistically significant.
In all 10 influenza seasons studied, non-Hispanic black children (hereafter referred to as 
black children) and Hispanic children had lower full influenza vaccination coverage than 
non-Hispanic white children (hereafter referred to as white children; Table 2; Fig 2). The 
gap in these racial/ethnic differences does not appear to decrease in magnitude over time. 
For example the percentage of black children fully vaccinated in the 2002–2003 season was 
2.7%, whereas the percentage of white children fully vaccinated was 6.1%, a difference of 
−3.4 percentage points; for the remaining seasons these black-white differences widen as 
follows: −7.3, −10.3, −11.9, −12.5, −13.7, −14.9, −14.2, −11.2, and −13.7 percentage points. 
The Hispanic-white differences by season were as follow: −3.4, −4.8, −8.2, −10.4, −8.6, 
−8.9, −9.6, −7.7, −5.3, and −8.8). In 7 of the 10 seasons, black children also had lower full 
influenza vaccination coverage than Hispanic children.
Similar racial/ethnic differences were also seen among the estimates of coverage with at 
least 1 dose of influenza vaccination (Table 2). In all 10 influenza seasons, black children 
had lower ≥1 dose influenza vaccination coverage than white children. In 8 of the 10 seasons 
Hispanic children had lower coverage than white children, whereas in the 2009–2010 and 
2010–2011 seasons they had similar coverage.
Full Influenza Vaccination Coverage by Number of Doses Required
Among children who required 1 dose to be fully vaccinated and among those who required 2 
doses, full influenza vaccination coverage increased from the 2002–2003 influenza season to 
the 2011–2012 season (trend test P < .001 each; Table 2). The change in vaccination 
coverage from one season to the next within each group and whether these changes were 
statistically significant is indicated in Table 2. For all 10 influenza seasons, full influenza 
vaccination coverage was higher among children requiring only 1 dose compared with those 
requiring 2 doses (Table 2). For the 2011–2012 season, among the subset of children 6 to 23 
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months who required 2 doses and received 1 dose, 63.7% received their required second 
dose, which can be viewed as the completion rate among those who began the series of 2 
doses (not shown in tables).
DISCUSSION
This study found that full influenza vaccination coverage of children 6 to 23 months 
increased from 4.8% in the 2002–2003 influenza season to 44.7% in the 2011–2012 season. 
This is to be expected because previously published reports of coverage with at least 1 dose 
of influenza vaccination have shown increases during this time.19,23 Despite the increase, the 
majority of children 6 to 23 months in the United States were not fully vaccinated against 
influenza.
Previous reports of full influenza vaccination coverage of children 6 to 23 months have been 
published using NIS provider-reported data, but these reports used a different estimation 
methodology (proportion estimate, subset of children 6 to 23 months during September–
December and only included vaccinations through January).24–29 The estimates from 
previous reports compared with the estimates in this report are as follows for the 2002–2003 
season through the 2009–2010 season: 4.4% versus 4.8%, 8.4% versus 9.1%, 17.8% versus 
19.2%, 20.6% versus 22.6%, 21.3% versus 26.1%, 23.4% versus 27.0%, 24.7% versus 
31.4%, 30.1% versus 34.4%, respectively.24–29 Note that the previous reports slightly 
underestimated full influenza vaccination coverage as expected because they did not count 
any vaccinations past January; reanalyzing these data using the improved Kaplan-Meir 
method rather than the proportion estimate, the censored nature of the data could be taken 
into account and all vaccinations counted. These reports were discontinued due to lack of 
timeliness of NIS provider-reported influenza data (ie, the estimates were not available 
before the start of the next influenza season due to the survey time needed to obtain 
provider-reported vaccination histories) and due to a need for influenza vaccination 
estimates for all children 6 months to 17 years. To address this, the NIS-Flu was developed, 
which can provide estimates of parental report of influenza vaccination coverage for children 
6 months to 17 years for an influenza season before the start of the following influenza 
season.19 Parental report of at least 1 dose of influenza vaccination has been reported based 
on the NIS-Flu data; however, parental report of full vaccination coverage has not yet been 
assessed. Full influenza vaccination coverage of children 6 to 23 months based on 
Immunization Information Systems sentinel site data compared with the national estimates 
from this report likewise showed slight differences: 35.9% versus 33.7%, respectively, for 
the 2010–2011 season and 44.3% versus 44.7%, respectively, for the 2011–2012 season.30
NIS estimates based on provider report are not as timely as estimates based on parental 
report due to the time needed to obtain vaccination information from all immunization 
providers. Additionally, for this study, 2 full calendar years of interviews were used for each 
influenza season to have a more equal age distribution of children 6 months, 7 months, and 
up to 23 months; if only 1 calendar year was used, the sample would be weighted more 
heavily toward older children. Use of parental reported influenza vaccination allows for the 
timely production of influenza vaccination coverage estimates.19 Obtaining parental report 
of full influenza vaccination, however, is more complicated because it requires the parental 
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report of several past seasons of influenza vaccination, which may be more subject to recall 
bias. A thorough analysis of the validity of parent- versus provider-reported child influenza 
vaccination is needed, including examining whether there are differences by race/ethnicity. 
Initial indications, when examining the estimated number of people vaccinated, are that 
parent report overestimates influenza vaccination coverage.19 At least 1 study did find 
differences in parental versus provider report by various sociodemographic characteristics, 
including race/ethnicity.31 The ≥1 dose coverage estimates in this report, based on provider 
report, are lower than those based on the parental-reported NIS-Flu estimates; a detailed 
validity study to quantify the extent of parental overreporting is warranted.19
Racial/ethnic differences in influenza vaccination coverage among adults have persisted over 
many influenza seasons.32 The finding that such differences also exist for full influenza 
vaccination coverage of young children is concerning. Broad use of evidence-based 
strategies that enhance access to vaccination services, increase demand for vaccinations, and 
use provider or system interventions are important components of efforts to increase 
vaccination coverage and reduce these differences.33 Furthermore, providers are encouraged 
to begin offering influenza vaccination soon after vaccine becomes available and to continue 
vaccination efforts throughout the influenza season. This is especially important for children 
who require 2 doses within the season to be fully protected.
This study is subject to at least 3 limitations. First, the NIS is a telephone survey followed by 
a mail survey to immunization providers. Although statistical adjustments compensate for 
nonresponse and households without telephones, bias might remain. Second, the NIS relies 
on provider reported vaccination histories; incomplete records and reporting might affect 
estimates. However, a previous study has shown that nearly all (97%) vaccinated children 
aged 6 to 23 months received their influenza vaccination at a medical place (74% at a 
doctor’s office, 18% at a clinic or health center, and 5% at a hospital or emergency 
department).30 Third, there was a change in the NIS sampling design from landline to dual 
frame (landline and cellular telephone), which should be taken into account when 
interpreting trends over time in NIS estimates.
CONCLUSIONS
Less than half of children aged 6 to 23 months in the United States are fully vaccinated 
against influenza, and even a smaller percentage of Hispanic and non-Hispanic black 
children. Appropriate implementation of evidence-based strategies is needed to increase the 
percentage of children who are fully vaccinated. Prevention of influenza among infants and 
young children is a public health priority because of their high risk for influenza-related 
complications.
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WHAT’S KNOWN ON THIS SUBJECT
Influenza vaccination coverage with ≥1 dose based on parental report has been routinely 
assessed and reported since 2009 in the United States at http://www.cdc.gov/flu/
fluvaxview, but full influenza vaccination coverage (by parent or provider report) has not 
been assessed since then.
WHAT THIS STUDY ADDS
This study reports the percentage of children 6 to 23 months in the United States who 
were fully vaccinated against influenza during each of 10 consecutive influenza seasons 
(2002–2003 through 2011–2012) by race/ethnicity based on provider reported data.
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FIGURE 1. 
Full influenza vaccination coverage among children aged 6 to 23 months by influenza 
season, NIS, provider report, United States, 2002–2003 through 2011–2012 influenza 
seasons. aEstimates obtained using Kaplan-Meier survival analysis methods and reported 
with 95% confidence interval half-widths.
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FIGURE 2. 
Full influenza vaccination coverage among children aged 6 to 23 months by influenza 
season and racial/ethnic group, NIS, provider report, United States, 2002–2003 through 
2012–2013 influenza seasons. aEstimates obtained using Kaplan-Meier survival analysis 
methods and reported with confidence interval half-widths. Estimates for the 2009–2010 
season include only the seasonal influenza vaccine and exclude the 2009 H1N1 
vaccine. bStatistically significant (P < .05) differences between groups as well as the 
direction of the differences are as follows: 2002–2003: H < W; H < O; B < W; B < O; 2003–
2004: H < W; H < O; B < H; B < W; B < O. 2004–2005: H < W; B < W; O < W; B < O; 
2005–2006: H < W; H < O; B < W; B < O; O < W; 2006–2007: H<W; B < H; H < O; B < 
W; B < O; 2007–2008: H < W; B < H; H < O; B < W; B < O; 2008–2009: H < W; B < H; H 
< O; B < W; B < O; 2009–2010: H < W; B < H; H < O; B<W; B < O; 2011–2012: H < W; B 
< H; B < W; W < O; B < O; 2012–2013: H < W; B < H; H < O; B < W; B < O, where H, 
Hispanic; W, white only, non-Hispanic; B, black only, non-Hispanic; O, other or multiple 
race, non-Hispanic. All other pairwise comparisons not noted were not statistically 
significant.
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TABLE 1
Full Influenza Vaccination Recommendations and Number of Doses Needed to be Fully Vaccinated, National 
Immunization Survey (NIS), Provider-Report, United States, 2002–2003 Through 2011–2012 Influenza 
Seasons
Influenza Season Recommendationsa Children 
Who 
Needed 2 
Doses, % 
± 95% CIb
2002–2003 “Among previously unvaccinated children aged <9 years, two doses administered >1 months apart are 
recommended for satisfactory antibody responses.“2 99.2 ± 0.2
2003–2004 “Among previously unvaccinated children aged <9 years, two doses administered >1 month apart are 
recommended for satisfactory antibody responses.”14 96.5 ± 0.4
2004–2005 “Among previously unvaccinated children aged <9 years, 2 doses administered >1 month apart are 
recommended for satisfactory antibody responses. If possible, the second dose should be administered 
before December. If a child aged <9 years receiving vaccine for the first time does not receive a second 
dose of vaccine within the same season, only 1 dose of vaccine should be administered the following 
season. Two doses are not required at that time.”3
92.0 ± 0.6
2005–2006 “Among previously unvaccinated children aged <9 years, 2 doses administered >1 month apart are 
recommended for satisfactory antibody responses. If possible, the second dose should be administered 
before December. If a child aged <9 years receiving vaccine for the first time does not receive a second 
dose of vaccine within the same season, only 1 dose of vaccine should be administered the following 
season. Two doses are not required at that time.”15
81.5 ± 0.8
2006–2007 “Among previously unvaccinated children aged 6 months–<9 years, 2 doses of inactivated vaccine 
administered >1 month apart are recommended for eliciting satisfactory antibody responses. If possible, the 
second dose should be administered before the onset of influenza season. If a child aged 6 months–<9 years 
receiving influenza vaccine for the first time does not receive a second dose of vaccine within the same 
season, only 1 dose of vaccine should be administered the following season. Two doses are not required at 
that time.”16
81.0 ± 1.0
2007–2008 “ACIP recommends 2 vaccine doses for children aged 6 months–8 years who received an influenza vaccine 
(either TIV or LAIV) for the first time in the previous season but who did not receive the recommended 
second dose of vaccine within the same season. ACIP recommendations are now harmonized with regard to 
this issue with those of AAP. This recommendation represents a change from the 2006 recommendations, in 
which children aged 6 months–8 years who received only 1 dose of vaccine in their first year of vaccination 
were recommended to receive only a single dose in the following season. ACIP does not recommend that a 
child receive influenza vaccine for the first time in the spring with the intent of providing a priming dose for 
the following season. Children recommended for vaccination who are in their third or more year of being 
vaccinated and who received only 1 dose in each of their first 2 years of being vaccinated should continue 
receiving a single annual dose.”17
88.7 ± 0.6
2008–2009 “All children aged 6 months–8 years who have not received vaccination against influenza previously should 
receive 2 doses of vaccine the first influenza season that they are vaccinated. The second dose should be 
administered 4 or more weeks after the initial dose. For example, children aged 6 months–8 years who were 
vaccinated for the first time during the 2007–08 influenza season but only received 1 dose during that 
season should receive 2 doses of the 2008–09 influenza vaccine. All other children aged 6 months–8 years 
who have previously received 1 or more doses of influenza vaccine at any time should receive 1 dose of the 
2008–09 influenza vaccine. Children aged 6 months–8 years who only received a single vaccination during 
a season before 2007–08 should receive 1 dose of the 2008–09 influenza vaccine.”18
87.6 ± 0.8
2009–2010 “All children aged 6 months–8 years who have not received vaccination against influenza previously should 
receive 2 doses of vaccine the first influenza season that they are vaccinated. The second dose should be 
administered 4 or more weeks after the initial dose. When only 1 dose is administered to children aged 6 
months–8 years during their first year of vaccination, 2 doses should be administered in the following 
season. However, 2 doses should only be administered in the first season of vaccination, or in the season 
that immediately follows if only 1 dose is administered in the first season. For example, children aged 6 
months–8 years who were vaccinated for the first time with the 2008–09 influenza vaccine but received 
only 1 dose should receive 2 doses of the 2009–10 influenza vaccine. All other children aged 6 months–8 
years who have previously received 1 or more doses of influenza vaccine at any time should receive 1 dose 
of the 2009–10 influenza vaccine. Children aged 6 months–8 years who received only a single vaccination 
during a season before 2007–08 should receive 1 dose of the 2009–10 influenza vaccine.”5
84.4 ± 0.8
2010–2011 “All children aged 6 months–8 years who receive a seasonal influenza vaccine for the first time should be 
administered 2 doses. Children aged 6 months–8 years who received a seasonal vaccine for the first time 
during 2009–2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010–2011. 
In addition, for the 2010–11 influenza season, children aged 6 months–8 years who did not receive at least 
1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010–11 seasonal 
90.3 ± 0.6
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Influenza Season Recommendationsa Children 
Who 
Needed 2 
Doses, % 
± 95% CIb
influenza vaccine, regardless of previous influenza vaccination history. Children aged 6 months–8 years for 
whom the previous 2009–10 seasonal or influenza A (H1N1) 2009 monovalent vaccine history cannot be 
determined should receive 2 doses of a 2010–11 seasonal influenza vaccine.”9
2011–2012 “Vaccination providers should note that, in previous seasons, children aged 6 months through 8 years who 
received only 1 dose of influenza vaccine in their first year of vaccination required 2 doses the following 
season. However, because the 2011–12 vaccine strains are unchanged from the 2010–11 season, children in 
this age group who received at least 1 dose of the 2010–11 seasonal vaccine will require only 1 dose of the 
2011–12 vaccine. Children in this age group who did not receive at least 1 dose of the 2010–11 seasonal 
influenza vaccine, or for whom it is not certain whether the 2010–11 seasonal vaccine was received, should 
receive 2 doses of the 2011–12 seasonal influenza vaccine.”10
70.1 ± 1.2
CI, confidence interval.
a
Recommendations regarding which children required 2 doses versus 1 dose to be fully vaccinated against influenza, as published in the annual 
“Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” published in Morbidity 
and Mortality Weekly Report.
bAged 6 to 23 months.
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4 
± 
1.
0
 
 
d.
 O
th
er
/
m
u
lti
pl
e 
ra
ce
, 
n
o
n
-H
isp
an
ic
10
.4
 ±
 2
.2
ac
24
.0
 ±
 3
.2
ac
+
13
.6
§
36
.3
 ±
 3
.3
bc
+
12
.3
§
39
.2
 ±
 3
.5
ac
+
2.
9
46
.0
 ±
 4
.0
ac
+
6.
8§
50
.6
 ±
 3
.7
ac
+
4.
6
51
.6
 ±
 4
.0
c
+
1.
0
59
.4
 ±
 3
.9
ab
c
+
7.
8§
61
.5
 ±
 3
.6
ab
c
+
2.
1
61
.8
 ±
 4
.0
ac
+
0.
3
5.
9 
± 
1.
2
CI
, c
on
fid
en
ce
 in
te
rv
al
 h
al
f-w
id
th
.
Th
e 
pr
es
en
ce
 o
r a
bs
en
ce
 o
f s
up
er
sc
rip
te
d 
le
tte
rs
 d
en
ot
es
 w
he
th
er
 th
at
 e
sti
m
at
e 
w
as
 s
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t a
t P
 
<
 .0
5 
fro
m
 an
ot
he
r r
ow
,
 
an
d 
de
no
te
s w
hi
ch
 ro
w
 it
 d
iff
er
ed
 fr
om
 (a
, b
, c
, o
r d
) b
ase
d 
o
n
 p
ai
rw
ise
 c
om
pa
ris
on
 t 
te
st
s.
 F
o
r 
ex
am
pl
e,
 in
 2
00
2–
20
03
, t
he
 p
er
ce
nt
ag
e 
of
 fu
lly
 v
ac
ci
na
te
d 
6-
 to
 1
1-
m
on
th
-o
ld
s (
a) 
wa
s 
st
at
ist
ic
al
ly
 si
gn
ifi
ca
nt
ly
 d
iff
er
en
t f
ro
m
 th
e 
pe
rc
en
ta
ge
 o
f f
ul
ly
 v
ac
ci
na
te
d 
17
- t
o 
23
-m
on
th
-o
ld
s (
c).
*
Te
st
s 
fo
r l
in
ea
r t
re
nd
 w
er
e 
pe
rfo
rm
ed
 u
sin
g 
a 
w
ei
gh
te
d 
lin
ea
r r
eg
re
ss
io
n 
on
 th
e 
se
as
on
-s
pe
ci
fic
 e
sti
m
at
es
 u
sin
g 
se
as
on
 n
um
be
r a
s t
he
 in
de
pe
nd
en
t v
ar
ia
bl
e 
an
d 
w
ei
gh
ts 
as
 th
e 
in
v
er
se
 o
f t
he
 e
sti
m
at
ed
 
v
ar
ia
nc
e 
of
 th
e 
es
tim
at
ed
 v
ac
ci
na
tio
n 
co
v
er
ag
e.
 T
he
 e
sti
m
at
ed
 sl
op
e 
co
ef
fic
ie
nt
s w
er
e 
in
te
rp
re
te
d 
as
 th
e 
av
er
ag
e 
ch
an
ge
 a
cr
os
s s
ea
so
ns
 a
ss
um
in
g 
a 
lin
ea
r i
nc
re
as
e.
 S
lo
pe
s a
nd
 th
ei
r 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s 
ar
e 
pr
es
en
te
d;
 a
ll 
of
 th
e 
te
sts
 fo
r l
in
ea
r t
re
nd
 w
er
e 
sig
ni
fic
an
t a
t P
 
<
 .0
01
.
*
*
Es
tim
at
es
 o
bt
ai
ne
d 
us
in
g 
K
ap
la
n-
M
ei
er
 su
rv
iv
al
 a
na
ly
sis
 m
et
ho
ds
.
† C
ha
ng
e 
in
 p
er
ce
nt
ag
e 
po
in
ts 
co
m
pa
re
d 
w
ith
 th
e 
pr
ev
io
us
 in
flu
en
za
 se
as
on
.
‡ P
ai
r-w
ise
 c
om
pa
ris
on
s b
et
w
ee
n 
ad
jac
en
t in
flu
en
za 
sea
son
s w
ere
 co
nd
uc
ted
 us
ing
 t t
es
ts
; s
ta
tis
tic
al
ly
 si
gn
ifi
ca
nt
 (P
 
<
 .0
5) 
dif
fe
re
nc
es
 a
re
 fo
ot
no
te
d.
A
ge
 o
n 
N
ov
em
be
r f
irs
t o
f t
he
 in
flu
en
za
 se
as
on
 u
nd
er
 st
ud
y.
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TA
B
LE
 3
Fu
ll 
In
flu
en
za
 V
ac
ci
na
tio
n 
Co
v
er
ag
e 
A
m
on
g 
Ch
ild
re
n 
6 
to
 2
3 
M
on
th
s b
y 
St
at
e, 
N
IS
, p
ro
v
id
er
 re
po
rt,
 U
ni
te
d 
St
at
es
, 2
01
1–
20
12
 In
flu
en
za
 S
ea
so
n
St
at
ea
Fu
ll 
In
flu
en
za
 V
a
cc
in
at
io
n 
%
 ±
 9
5%
 C
Ib
St
at
e
Fu
ll 
In
flu
en
za
 V
a
cc
in
at
io
n 
%
 ±
 9
5%
 C
Ia
St
at
e
Fu
ll 
In
flu
en
za
 V
a
cc
in
at
io
n 
%
 ±
 9
5%
 C
Ia
M
as
sa
ch
us
et
ts
72
.2
 ±
 6
.1
Co
lo
ra
do
50
.6
 ±
 7
.2
Fl
or
id
a
39
.1
 ±
 7
.1
Co
nn
ec
tic
ut
71
.1
 ±
 6
.4
N
ew
 Y
o
rk
50
.4
 ±
 4
.5
A
la
sk
a
38
.9
 ±
 6
.1
R
ho
de
 Is
la
nd
65
.3
 ±
 6
.7
A
riz
on
a
49
.9
 ±
 7
.0
K
an
sa
s
38
.7
 ±
 6
.2
Ve
rm
o
n
t
64
.9
 ±
 6
.1
N
ew
 M
ex
ic
o
48
.2
 ±
 6
.5
Te
n
n
es
se
e
38
.6
 ±
 6
.5
D
el
aw
ar
e
64
.5
 ±
 6
.7
Ill
in
oi
s
48
.0
 ±
 4
.7
U
ta
h
38
.3
 ±
 6
.4
M
in
ne
so
ta
63
.6
 ±
 6
.9
W
as
hi
ng
to
n
47
.8
 ±
 7
.2
Te
x
as
36
.7
 ±
 4
.1
N
ew
 H
am
ps
hi
re
62
.7
 ±
 6
.3
M
ic
hi
ga
n
47
.7
 ±
 7
.0
Io
w
a
34
.9
 ±
 6
.9
So
ut
h 
D
ak
o
ta
60
.1
 ±
 6
.8
Vi
rg
in
ia
47
.6
 ±
 8
.6
K
en
tu
ck
y
34
.5
 ±
 6
.7
H
aw
ai
i
57
.7
 ±
 6
.6
O
hi
o
45
.7
 ±
 6
.6
Lo
ui
sia
na
33
.8
 ±
 6
.3
W
isc
on
sin
57
.5
 ±
 6
.6
N
or
th
 C
ar
ol
in
a
44
.1
 ±
 6
.7
W
es
t V
irg
in
ia
33
.5
 ±
 6
.9
Pe
nn
sy
lv
an
ia
56
.7
 ±
 5
.3
M
ar
yl
an
d
44
.0
 ±
 7
.0
G
eo
rg
ia
33
.2
 ±
 7
.0
N
eb
ra
sk
a
56
.6
 ±
 6
.4
O
re
go
n
43
.7
 ±
 6
.2
A
la
ba
m
a
32
.9
 ±
 7
.1
N
or
th
 D
ak
o
ta
56
.2
 ±
 6
.5
Ca
lif
or
ni
a
43
.0
 ±
 6
.8
W
yo
m
in
g
32
.2
 ±
 6
.7
M
ai
ne
55
.4
 ±
 6
.8
M
on
ta
na
42
.1
 ±
 6
.8
O
kl
ah
om
a
31
.8
 ±
 6
.3
N
ew
 Je
rs
ey
55
.2
 ±
 6
.3
In
di
an
a
42
.0
 ±
 6
.7
So
ut
h 
Ca
ro
lin
a
31
.6
 ±
 6
.3
D
ist
ric
t o
f C
ol
um
bi
a
54
.3
 ±
 7
.1
Id
ah
o
41
.6
 ±
 7
.2
A
rk
an
sa
s
26
.6
 ±
 6
.3
M
iss
ou
ri
51
.6
 ±
 7
.4
N
ev
ad
a
40
.8
 ±
 6
.2
M
iss
iss
ip
pi
23
.6
 ±
 6
.3
CI
, c
on
fid
en
ce
 in
te
rv
al
 h
al
f-w
id
th
.
a O
rd
er
ed
 fr
om
 h
ig
he
st 
to
 lo
w
es
t f
ul
l i
nf
lu
en
za
 v
ac
ci
na
tio
n 
co
v
er
ag
e.
b E
st
im
at
es
 o
bt
ai
ne
d 
us
in
g 
K
ap
la
n-
M
ei
er
 su
rv
iv
al
 a
na
ly
sis
 m
et
ho
ds
.
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